ELSEVIER

Vol. 191, issues 1–2, 15 October 2001

CONTENTS

Journal of the Neurological Sciences

www.elsevier.com/locate/jns

Abstracted/indexed in: Biological Abstracts (BIOSIS) – Chemical Abstracts – Current Awareness in Biological Sciences (CABS) – Current Contents/Life Sciences – EMBASE – Index Medicus – Medline – Neurosciences Citation Index – Pascal et Francis (INST-CNRS) – PubMed – Reference Update (via Research Information Systems) – Research Alert – Science Citation index – Science Citation Index – Expanded (SciSearch or ISI Web of Science)

Full text available in ScienceDirect® and Neuroscion.

Special Issue

Advances in Amyotrophic Lateral Sclerosis

Papers from the 11th International Symposium on Amyotrophic Lateral Sclerosis/ Motor Neuron Disease held in Arhus, Denmark on 4–6 December 2000

Preface 1

The epidemiology of motor neuron diseases: a review of recent studies
P.M. Worms (France) 3

ALS with variable phenotypes in a six-generation family caused by leu144phe mutation in the *SOD1* gene
G. Masè, S. Ros, A. Gemma, L. Bonfigli, N. Carraro, G. Cazzato, M. Rolfo, F. Zanconati, J. Sepcic, A. Jurjevic, D. Pirulli, M. Boniotto, S. Zezlina, S. Crovella and A. Amoroso (Italy, Croatia) 11

Functional diversity of recombinant human AMPA type glutamate receptors: possible implications for selective vulnerability of motor neurons
K. Krampfl, F. Schlesinger, H. Wolfes, R. Dengler and J. Bufler (Germany) 19

Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity
C. Bendotti, N. Calvaresi, L. Chiveri, A. Prelle, M. Moggio, M. Braga, V. Silani and S. De Biasi (Italy) 25

Imaging and neurochemical markers for diagnosis and disease progression in ALS
J. Karitzky and A.C. Ludolph (Germany) 35

A protocol for identification of early bulbar signs in amyotrophic lateral sclerosis
L.J. Ball, A. Willis, D.R. Beukelman and G.L. Pattee (USA) 43

Quantitative assessment of motor fatigue in amyotrophic lateral sclerosis
M. Sanjak, J. Brinkmann, D.S. Belden, K. Roelke, A. Waclawik, H.E. Neville, S.P. Ringel, J.R. Murphy and B.R. Brooks (USA) 55

Impaired oxidative metabolism in exercising muscle from ALS patients
G. Siciliano, E. Pastorini, L. Pasquali, M.L. Manca, A. Iudice and L. Murri (Italy) 61

Electromyography of respiratory muscles in amyotrophic lateral sclerosis
H. Stewart, A. Eisen, J. Road, M. Mezei and M. Weber (Canada, Switzerland) 67

A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients
C.E. Jackson, J. Rosenfeld, D.H. Moore, W.W. Bryan, R.J. Barohn, M. Wrench, D. Myers, L. Heberlin, R. King, J. Smith, D. Gelinas and R.G. Miller (USA) 75

Quality of life issues in motor neurone disease: the development and validation of a coping strategies questionnaire, the MND Coping Scale
J.N. Lee, S.A. Rigby, F. Burchardt, E.W. Thornton, C. Dougan and C.A. Young (UK) 79

Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis
G.M. Kiebert, C. Green, C. Murphy, J.D. Mitchell, M. O'Brien, A. Burrell and P.N. Leigh (UK) 87

The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK
M. Tavakoli and M. Malek (UK) 95

Patients' assessment of quality of life instruments: a randomised study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis
C. Neudert, M. Wasner and G.D. Borasio (Germany) 103

External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis
P.M. Andersen, H. Grönberg, L. Franzen and U. Funegård (Sweden) 111

Incidence and predictors of PEG placement in ALS/MND
S.M. Albert, P.L. Murphy, M. Del Bene, L.P. Rowland and H. Mitsumoto (USA) 115

Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS
G.J. Groeneveld, H.J.M. Van Kan, J. Sastre Toraño, J.H. Veldink, H.-J. Guchelaar, J.H.J. Wokke and L.H. van den Berg (The Netherlands) 121

A placebo-controlled trial of gabapentin in spinal muscular atrophy
R.G. Miller, D.H. Moore, V. Dronsky, W. Bradley, R. Barohn, W. Bryan, T.W. Prior, D.F. Gelinas, S. Iannaccone, J. Kissel, R. Leshner, J. Mendell, M. Mendoza, B. Russman, F. Samaha, S. Smith and SMA Study Group (USA) 127

The value of muscle exercise in patients with amyotrophic lateral sclerosis
V.E. Drory, E. Goltsman, J. Goldman Reznik, A. Mosek and A.D. Korczyn (Israel) 133
Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results
L. Mazzini, C. Balzarini, R. Colombo, G. Mora, I. Pastore, R. De Ambrogio and M. Caligari (Italy) 139
Amyotrophic lateral sclerosis care in Italy: a nationwide study in neurological centers
A. Chiò, V. Silani and Italian ALS Study Group (Italy) 145
The use of alternative medicine by patients with amyotrophic lateral sclerosis
M. Wasner, H. Klier and G.D. Borasio (Germany) 151

Calendar of Events 155

Instructions to Authors 157